MDTHealthcare · Medical DevicesThe 29 Wall Street analysts covering Medtronic PLC hold a median 12-month price target of $104 — +11.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 2 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Medtronic PLC on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Momentum (55): The shares have been drifting down relative to others.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MDT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +11.7% from it.
Of the 20 most recent actions, 3 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Aug 2026 | TD Cowen | Maintains | Buy | $100 → $110 |
| 27 Aug 2026 | Needham | Maintains | Buy | $101 → $114 |
| 18 Aug 2026 | BTIG | Reiterates | Buy | $91 |
| 18 Aug 2026 | BTIG | Reiterates | Buy | — |
| 28 July 2026 | UBS | Upgrade | Buy | — |
| 28 July 2026 | UBS | Upgrade | Buy | $85 → $100 |
| 10 July 2026 | TD Cowen | Maintains | Buy | — |
| 10 July 2026 | TD Cowen | Maintains | Buy | $119 → $100 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $106 → $105 |
| 17 June 2026 | Needham | Reiterates | Buy | — |
| 5 June 2026 | Bernstein | Maintains | Outperform | — |
| 5 June 2026 | Goldman Sachs | Maintains | Neutral | — |
| 4 June 2026 | Baird | Maintains | Neutral | — |
| 4 June 2026 | BTIG | Upgrade | Buy | — |
| 4 June 2026 | Leerink Partners | Maintains | Outperform | — |
| 4 June 2026 | RBC Capital | Reiterates | Outperform | — |
| 4 June 2026 | TD Cowen | Reiterates | Buy | — |
| 4 June 2026 | UBS | Maintains | Neutral | — |
| 4 June 2026 | Wells Fargo | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MDT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 3 Sept 2026, Medtronic PLC returned +4.2% against +21.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 31% of US stocks
Cheaper than 39% of US stocks
Cheaper than 40% of US stocks
Cheaper than 27% of US stocks
Higher than 52% of US stocks
Higher than 56% of US stocks
Higher than 79% of US stocks
Higher than 81% of US stocks
Higher than 75% of US stocks
Higher than 63% of US stocks
Higher than 76% of US stocks
Higher than 66% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Medtronic PLC has a market value of $118.0B and an enterprise value of $136.6B.
Revenue in the twelve months to 30 Apr 2026: $36.4B. The latest quarter grew 9.9% year on year.
Net income over the same four quarters: $4.8B, a 13.3% net margin.
Diluted earnings per share, trailing twelve months: $3.73.
Free cash flow in the twelve months to 30 Apr 2026: $5.4B, after $1.9B of capital spending.
Medtronic PLC spent $1.0B on share buybacks and $3.6B on dividends in the twelve months to 30 Apr 2026.
Trailing P/E: 24.7×; forward P/E: 14.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 3.12%, paying out 76% of earnings.
Medtronic PLC employs 95,000 people — $383K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Medtronic PLC — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Medtronic's growth is accelerating as its cardiovascular business expands, and the company is close to becoming a Dividend King. The article also suggests the stock remains attractively valued.
Why it matters — This item highlights accelerating growth, potential Dividend King status, and valuation, which are key factors for investors tracking Medtronic's outlook.
Zacks Investment Research highlights Medtronic as a top momentum stock for the long term, using its Style Scores system from the Zacks Premium research service to identify the stock as a strong option for momentum-focused investors.
Why it matters — The recognition signals that MDT is viewed favorably by analysts for its long-term momentum characteristics, which is relevant for investors tracking the stock.
Medtronic raised its fiscal 2027 outlook during its Q1 earnings call, citing broadened growth across major franchises and newer platforms. The company noted that investments in robotics and ablation technologies are advancing.
Why it matters — A raised fiscal 2027 outlook with growth across both established franchises and newer platforms signals expanding momentum for Medtronic's diversified portfolio.
Zacks Investment Research highlights Medtronic as a top growth stock for the long term, citing the Zacks Style Scores tool that helps investors identify well-rated stocks based on their investing style.
Why it matters — MDT watchers would care because the report signals that the company is regarded favorably by an independent research firm using its style-based stock-rating methodology.
Medtronic reported better-than-expected first-quarter financial results on Tuesday and raised its fiscal 2027 adjusted EPS guidance. Following the upbeat results, analysts raised their forecasts for the company.
Why it matters — MDT watchers would care because a strong first-quarter beat and raised full-year guidance signal improving financial performance for the company.
The 29 Wall Street analysts covering Medtronic PLC have a median 12-month price target of $104, with estimates ranging from $78 to $121. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 29 analysts covering Medtronic PLC, 20 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Medtronic PLC 82 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 2 Sept 2026, Medtronic PLC ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
No one can know that. What the data says: the median 12-month target from 29 analysts implies +11.7% from the last close, and Ticker Nerd's factor model ranks Medtronic PLC 82 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Medtronic PLC publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $78 to $121 over the next 12 months.
Medtronic PLC returned +4.2% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Medtronic plc is a global medical technology company that develops, manufactures, and sells device-based therapies and healthcare solutions. Its portfolio spans cardiovascular care, neuroscience, medical surgical products, and diabetes management, supporting the diagnosis, treatment, and monitoring of a wide range of chronic and complex conditions.
The most recent item we track (The Motley Fool, 3 Sept 2026): "4 Reasons to Buy Medtronic Stock Like There's No Tomorrow". Medtronic's growth is accelerating as its cardiovascular business expands, and the company is close to becoming a Dividend King. The article also suggests the stock remains attractively valued.
Medtronic plc is a global medical technology company that develops, manufactures, and sells device-based therapies and healthcare solutions. Its portfolio spans cardiovascular care, neuroscience, medical surgical products, and diabetes management, supporting the diagnosis, treatment, and monitoring of a wide range of chronic and complex conditions. Medtronic supplies hospitals, clinics, physicians, and other healthcare providers with products such as cardiac rhythm devices, neuromodulation systems, surgical instruments, insulin pumps, and patient monitoring technologies. The company serves healthcare systems across the United States and international markets, making it an important participant in modern medical device supply chains and clinical care delivery. Headquartered in Dublin, Ireland, Medtronic plc focuses on technologies used in everyday care and advanced procedures, helping healthcare professionals address conditions across many specialties.
CEO Mr. Geoffrey Straub Martha · 95,000 employees · Ireland · https://www.medtronic.com
